04 May 2020

REMDESIVIR: GILEAD IS DONATING ITS SUPPLY, BUT WHAT’S A FAIR PRICE?

  How much should Gilead Sciences charge for its now-authorized COVID-19 therapy remdesivir? Up to $4,460 per patient, an influential pricing watchdog figures. While Gilead has yet to present a marketing plan for the first coronavirus treatment to have shown clinical benefits in a well-designed randomized study, the Institute for Clinical and

0
31 Mar 2020

U.S. TAXPAYERS PAID MILLIONS TO DESIGN A LOW-COST VENTILATOR FOR A PANDEMIC: INSTEAD, A ROYAL PHILIPS N.V. SUBSIDIARY IS SELLING VERSIONS OF IT OVERSEAS.

    By Patricia Callahan, Sebastian Rotella and Tim Golden ProPublica   Five years ago, the U.S. Department of Health and Human Services tried to plug a crucial hole in its preparations for a global pandemic, signing a $13.8 million contract with a Pennsylvania manufacturer to create a low-cost, portable, easy-to-use ventilator that

0